How much funding has AVEO Oncology raised?

AVEO Oncology has raised $151.0M in total funding, most recently a Venture Round.

When was AVEO Oncology founded?

AVEO Oncology was founded in 2001.

Where is AVEO Oncology headquartered?

AVEO Oncology is headquartered in Boston, Massachusetts, United States.

What industry is AVEO Oncology in?

AVEO Oncology operates in Biotech, Oncology.

How many employees does AVEO Oncology have?

AVEO Oncology has 51-200 employees.

AVEO Oncology

Q: Who are AVEO Oncology's investors?

AVEO Oncology's investors include MPM Capital, Highland Capital Management, Biogen, LG Chem.

Acquired

Advancing Cancer Treatment Innovation

Boston, United States · Founded 2001 · $151.0M raised

Biotech

Oncology

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2001
Business Model: B2B

Website: aveooncology.com
Total Funding: $151.0M
Last Round: $151.0M Venture Round
Rounds: 1

About

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. Founded in 2001 and headquartered in Boston, Massachusetts, AVEO markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma. In January 2023, AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc., and continues to operate under the AVEO Oncology name.

Summary

AVEO Oncology is a Biotech company based in Boston, United States, founded in 2001. It has raised $151.0M in total across 1 round. Investors include MPM Capital, Highland Capital Management and Biogen.

LinkedIn X (Twitter)